文献速递急性肾损伤

非编码RNA在急性肾损伤中的作用

Noncoding RNAs in acute kidney injury.
PubMed 文献 · Kidney Int · 2018-01-01

急性肾损伤约影响50%的重症监护患者,当前诊断依赖肌酐尿素水平和尿量。本综述汇总microRNA、长链非编码RNA和环状RNA在AKI发病机制中的角色,讨论其作为生物标志物和治疗靶点的潜力及临床转化挑战。microRNA已进入临床测试,长链非编码RNA和环状RNA仍需临床前和临床试验验证。

要点

  • 非编码RNA在AKI时表达受调控,可作为早期诊断的候选标志物。
  • microRNA已进入临床测试阶段,长链非编码RNA和环状RNA尚需验证。
  • 非编码RNA有望成为AKI治疗靶点,但临床转化仍面临挑战。

核心结论

  • 非编码RNA在AKI发病机制中起重要作用,具生物标志物和治疗靶点潜力。
  • microRNA已进入临床测试,长链非编码RNA和环状RNA需进一步临床试验验证。

研究设计与样本

  • 综述文章,汇总非编码RNA(microRNA、长链非编码RNA、环状RNA)在AKI中的研究进展。

主要发现

  • AKI主要发生于脓毒症、急性缺血、肾毒性和缺氧后,导致肾脏严重损伤和死亡风险增加。
  • 非编码RNA是基因表达和蛋白合成的重要调控分子,其失调常与疾病发展相关。
  • 非编码RNA存在于肾脏和体液中,在AKI时表达受调控。

关键数值与推荐

  • AKI影响约50%的重症监护病房患者。
  • 当前AKI诊断基于肌酐尿素水平和尿量。

临床怎么用

  • 新型非编码RNA标志物可能提高AKI早期诊断准确性,利于早期预防和治疗。
  • 早期诊治有望减少肾脏替代治疗需求并降低死亡率。

局限性

  • 长链非编码RNA和环状RNA作为AKI生物标志物或治疗靶点仍需临床前和临床试验验证。
  • 非编码RNA研究向临床应用转化面临挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury (AKI) is an important health issue concerning ∼50% of patients treated in intensive care units. AKI mainly occurs after sepsis, acute ischemia, nephrotoxicity, or hypoxia and leads to severe damage of the kidney and to an increased risk of mortality. The diagnosis of AKI is currently based on creatinine urea levels and diuresis. Yet, novel markers may improve the accuracy of this diagnosis at an early stage of the disease, thereby allowing early prevention and therapy, ultimately leading to a reduction in the need for renal replacement therapy and decreased mortality. Non-protein-coding RNAs or noncoding RNAs are central players in development and disease. They are important regulatory molecules that allow a fine-tuning of gene expression and protein synthesis. This regulation is necessary to maintain homeostasis, and its dysregulation is often associated with disease development. Noncoding RNAs are present in the kidney and in body fluids and their expression is modulated during AKI. This review article assembles the current knowledge of the role of noncoding RNAs, including microRNAs, long noncoding RNAs and circular RNAs, in the pathogenesis of AKI. Their potential as biomarkers and therapeutic targets as well as the challenges to translate research findings to clinical application are discussed. Although microRNAs have entered clinical testing, preclinical and clinical trials are needed before long noncoding RNAs and circular RNAs may be considered as useful biomarkers or therapeutic targets of AKI.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Brandenburger T, Salgado Somoza A, Devaux Y, et al. Noncoding RNAs in acute kidney injury. Kidney Int. 2018. PMID: 30348304. doi:10.1016/j.kint.2018.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。